RaQualia Pharma Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From RaQualia Pharma Inc.
Ventus Therapeutics raised a $140m series C while Endeavor Biomedicines brought in $101m in series B cash. Also, Twist Bioscience grossed $250m in a follow-on offering, BioMarin raised $110m when it sold a priority review voucher and Nuvectis, TC BioPharm launched IPOs.
In the latest in a string of deals, Takeda's agreement to acquire global rights to Altos's gastroparesis candidate - and possibly the company itself - gives the Japanese giant another asset in its core gastrointestinal area.
The Japanese peptide venture Interprotein is tapping into artificial intelligence technology with the hope of improving the efficiency and accuracy of its drug discovery efforts.
RaQualia Pharma sees a new collaboration with Nagoya University as having two main benefits: aiding its effort to find innovative new drugs and helping to control operational expenses.
- Other Names / Subsidiaries
- AskAt Inc.